Seminal
The magazine and atlas of EU-funded researchA new publication from the web and AI team at Scott Charnley

Atlas / Netherlands

Marie Skłodowska-Curie Action · Running

BIO-MICRO BIO-MICRO: Biomarkers and Intervention Outcomes in Micronutrient Optimization

Coordinator
Stichting Amsterdam Umc, Netherlands
Runs
1 March 2026 to 28 February 2030
Status
Running
EU funding
€3.9m
Total cost
—
Partners
14 organisations in 4 countries
Type
Marie Skłodowska-Curie Action
Grant agreement
101226686

What the project is doing

In the project's own words, from its summary on CORDIS.

European micronutrient (MN) guidelines explicitly recommend to replete any MN deficiency in critically ill patients. MNs are crucial for immune defence, cellular metabolism and as antioxidant. Critically ill patients have increased requirements for MNs which can result in severe deficiencies and worse clinical outcomes. There are currently no accurate methods to diagnose MN deficiencies in critically ill patients. MN plasma concentrations are substantially affected by inflammation.

MN concentrations in erythrocytes and leukocytes or new functional markers may better reflect real deficiencies. Furthermore, most intervention trials with high-dose MN monotherapy yielded mixed results on clinical outcomes. Due to the absence of accurate monitoring tools of MN body status, all patients received fixed high-dose MN monotherapy. Personalized MN therapy based on subphenotyping of patients and accurate estimation of individual metabolic demands in all phases of disease may yield better outcome than this one-size-fits-all strategy.

In addition, more insight in the complex interplay between MNs and the role of MNs in post-ICU phase is necessary to guide future trials. BIO-MICRO consists of physicians, biologists, methodologists, trialists, health scientists, clinical chemists, patient representatives and industrial participants and aims to train innovative research fellows with interdisciplinary and intersectoral skills to develop the urgently needed strategies for MN personalized therapy in critically ill patients.

They will develop new analytics for reliably determination MN body status, investigate subphenotypes of patients likely to benefit from MN therapy, enable guidance with appropriate timing of MN therapy, investigate the interplay between MNs and explore the role of MNs in the rehabilitation phase. This will ultimately lead to significantly decreased mortality and organ dysfunctions, shorter ICU stay, improvement of quality of life and significant cost reductions.

Topics

Who is involved

OrganisationCityCountryRole
Stichting Amsterdam UmcAmsterdamNetherlandsCoordinator
Charite - Universitaetsmedizin BerlinBerlinGermanyParticipant
Deutsches Institut Fuer Ernaehrungsforschung Potsdam RehbrueckeNuthetalGermanyParticipant
Universitaet PotsdamPotsdamGermanyAssociatedpartner
Universitaetsklinikum Wuerzburg - Klinikum Der Bayerischen Julius-Maximilians-UniversitatWurzburgGermanyParticipant
Randox TeorantaDonegallIrelandParticipant
Universita Degli Studi Di FoggiaFoggiaItalyParticipant
DeWolfPact b.v.The HagueNetherlandsAssociatedpartner
Diagnotix BVAppingedamNetherlandsAssociatedpartner
Reiner Haga Medisch Diagnostisch Centrum BVDelftNetherlandsParticipant
Stichting VuAmsterdamNetherlandsAssociatedpartner
Stichting Ziekenhuis Gelderse ValleiEde GldNetherlandsParticipant
Stichting Martini ZiekenhuisGroningenNetherlandsParticipant
Wageningen UniversityWageningenNetherlandsAssociatedpartner

Source: CORDIS, European Commission. Data of 5 Nov 2026, reused under the Commission's reuse policy. View on CORDIS